

Sheet 1 of 11

Form PTO-1449  
Commerce

Department of

Patent and Trademark Office

Atty. Docket No.  
575-55873-BA-PCT-  
US/JPW/AJM/AABSerial No.  
10/665,867Applicant(s)  
Ann Marie Schmidt, et al.Filing Date  
September 19, 2003

Group Art Unit

INFORMATION DISCLOSURE CITATION  
(Use several sheets if necessary)

## U.S. PATENT DOCUMENTS

Examiner Initials	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
<i>HA</i>	5 6 8 8 6 5 3	11/18/97	Ulrich, et al.			
	5 8 6 4 0 1 8	1/26/99	Morser, et al.			
	5 9 7 6 8 3 2	11/2/99	Hitomi, et al.			

## FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
<i>HA</i>	WO	9 7 3 9 1 2 1	10/23/97	PCT				
<i>HA</i>	WO	9 7 3 9 1 2 5	10/23/97	PCT				

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)


<i>HA</i>	Baynes, J. W. (1991). Role of oxidative stress in development of complications in diabetes. Diabetes 40:405-412;
	Borchelt, D. R., et al. (1996). Familial Alzheimer's Disease-linked presenilin 1 variants elevate A $\beta$ 1-42/1-40 ratio in vitro and in vivo. Neuron 17: 1005-1013;
	Brett, J., et al. (1993). Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues. Am. J. Pathol. 143(6):1699-1712;
	Brownlee, M. (1992). Glycation products and the pathogenesis of diabetic complications. Diabetes Care 15(12):1835-1842;
	Cai, X-D., et al. (1993). Release of excess amyloid $\beta$ protein from a mutant amyloid $\beta$ protein precursor. Science 259: 514-516;
<i>✓</i>	Citron, M., et al. (1997). Mutant presenilins of Alzheimer's Disease increase production of 42-residue amyloid $\beta$ -protein in both transfected cells and transgenic mice. Nature Medicine 3(1): 67-72;

EXAMINER

DATE CONSIDERED

*Gregory Kimb* *10/11/05*  
\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.





Form PTO-2449 U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 575-55873-BA-PCT- US/JPW/AJM/AAB	Serial No. 10/665,867
	Applicant(s) Ann Marie Schmidt, et al.	
	Filing Date September 19, 2003	Group Art Unit

**INFORMATION DISCLOSURE CITATION**  
(Use several sheets if necessary)

**U.S. PATENT DOCUMENTS**

Examiner Initials	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate

**FOREIGN PATENT DOCUMENTS**

Examiner Initials	Document Number	Date	Name	Class	Subclass	Translation	
						Yes	No


**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**


AKG	Hori, O., et al. (1995). The Receptor for Advanced Glycation End Products (RAGE) Is a Cellular Binding Site for Amphotericin B. J. Biol. Chem. 270: 25752-25761;
	Khoury, J. E., et al., (1994). Macrophages adhere to glucose-modified basement membrane collagen IV via their scavenger receptors. J. Biol. Chem. 269: 10197-10200;
	Kuo, Y-M., et al. (1996). Water-soluble A $\beta$ (N-40, N-42) oligomers in normal and Alzheimer Disease brains. J. Biol. Chem. 271(8): 4077-4081;
	Lander, H. M., et al. (1997). Activation of the receptor for advanced glycation end products triggers a p21 <sup>ras</sup> dependent mitogen-activated protein kinase pathway regulated by oxidant stress. J. Biol. Chem. 272: 17810-17814;
V	Ledesma, M. D., et al. (1994). Analysis of microtubule-associated protein tau glycation in paired helical filaments. J. Biol. Chem. 269(34):21614-21619;

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449				U.S. Department of Commerce Patent and Trademark Office		Atty. Docket No. 575-55873-BA-PCT- US/JPW/AJM/AAB		Serial No. 10/665,867				
						Applicant(s) Ann Marie Schmidt, et al.		Filing Date September 19, 2003		Group Art Unit		
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)												
U.S. PATENT DOCUMENTS												
Examiner Initials		Document Number				Date	Name		Class	Subclass	Filing Date If Appropriate	
FOREIGN PATENT DOCUMENTS												
Examiner Initials		Document Number				Date	Name		Class	Subclass	Translation Yes No	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)												
[Signature]		Li, J. and A.M. Schmidt (1997). Characterization and functional analysis of the promoter of RAGE, the receptor for advanced glycation end products. J. Biol. Chem. 272: 16498-16506;										
[Signature]		Lorenzo, A. and B.A. Yanker (1994). $\beta$ -amyloid neurotoxicity requires fibril formation and is inhibited by Congo red. Proc. Nat. Acad. Sci. USA 91: 12243-12247;										
[Signature]		Mattson, M. P. and Y. Goodman (1995). Different amyloidogenic peptides share a similar mechanism of neurotoxicity involving reactive oxygen species and calcium. Brain Res. 676: 219-224;										
[Signature]		Miyata, T., et al. (1996). The receptor for advanced glycation end products (RAGE) is a central mediator of the interaction of AGE- $\beta$ 2 Microglobulin with human mononuclear phagocytes via an oxidant-sensitive pathway. J. Clin. Invest. 98: 1088-1094;										
EXAMINER		DATE CONSIDERED										
[Signature]		10/11/05										
*EXAMINER: Initial citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.												



Form PTO-1449

U.S. Department of Commerce  
Patent and Trademark OfficeAtty. Docket No.  
575-55873-BA-PCT-  
US/JPW/AJM/AABSerial No.  
10/665,867Applicant(s)  
Ann Marie Schmidt, et al.Filing Date  
September 19, 2003

Group Art Unit

**INFORMATION DISCLOSURE CITATION**  
(Use several sheets if necessary)**U.S. PATENT DOCUMENTS**

Examiner Initials	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate

**FOREIGN PATENT DOCUMENTS**

Examiner Initials	Document Number	Date	Name	Class	Subclass	Translation	
						Yes	No


**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

	Nakamura, Y., et al. (1993). Immunohistochemical localization of advanced glycosylation endproducts in coronary atheroma and cardiac tissue in diabetes mellitus. Am. J. Pathol. 143(6): 1649-1656;
	Neeper, M., et al. (1992). Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J. Biol. Chem. 267: 14998-15004;
	Palinski, W., et al. (1995). Immunological evidence for the presence of advanced glycosylation end products in atherosclerotic lesions of euglycemic rabbits. Arterioscl. Thromb. and Vasc. Biol. 15(5): 571-582;
	Park, L., et al. (1998). Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nature Medicine 4: 1025-1031;
	Park, L., et al. (1997). A murine model of accelerated diabetic atherosclerosis: suppression by soluble receptor for advanced glycation endproducts. Circulation Supplement. Abstract 3079;

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



<b>Form PTO-1489</b> <b>U.S. Department of Commerce</b> <b>Patent and Trademark Office</b>	<b>Atty. Docket No.</b> 575-55873-BA-PCT- US/JPW/AJM/AAB	<b>Serial No.</b> 10/665,867
	<b>Applicant(s)</b> Ann Marie Schmidt, et al.	
	<b>Filing Date</b> September 19, 2003	<b>Group Art Unit</b>

**INFORMATION DISCLOSURE CITATION**  
(Use several sheets if necessary)

**U.S. PATENT DOCUMENTS**

Examiner Initials	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate

**FOREIGN PATENT DOCUMENTS**

Examiner Initials	Document Number	Date	Name	Class	Subclass	Translation	
						Yes	No

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

HE	Reddy, S., et al. (1995). N <sup>c</sup> -(Carboxymethyl)lysine is a dominant advanced glycation end product (AGE) antigen in tissue proteins. Biochemistry 34: 10872-10878;
	Renard, C., et al. (1997). Recombinant advanced glycation end product receptor pharmacokinetics in normal and diabetic rats. Mol. Pharm. 52: 54-62;
	Ritthaler, U., et al. (1995). Expression of receptors for advanced glycation end products in peripheral occlusive vascular disease, Am. J. Pathol. 146: 688-694;
	Roher, A. E., et al. (1996). Morphology and toxicity of A $\beta$ -(1-42) dimer derived from neuritic and vascular amyloid deposits of Alzheimer's Disease. J. Biol. Chem. 271(34): 20631-20635;
	Schleicher, E. D., et al. (1997). Increased accumulation of the glycooxidation product N <sup>c</sup> -(carboxymethyl)lysine in human tissues in diabetes and aging. J. Clin. Invest. 99: 457-468;

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Form PTO-1449 U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 575-55873-BA-PCT- US/JPW/AJM/AAB	Serial No. 10/665,867
	Applicant(s) Ann Marie Schmidt, et al.	
	Filing Date September 19, 2003	Group Art Unit

**INFORMATION DISCLOSURE CITATION**  
(Use several sheets if necessary)

**U.S. PATENT DOCUMENTS**

Examiner Initials	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate

**FOREIGN PATENT DOCUMENTS**

Examiner Initials	Document Number	Date	Name	Class	Subclass	Translation	
						Yes	No

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

	Schmidt, A. M., et al. (1995). Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. J. Clin. Invest. 96: 1395-1403;
	Schmidt, A. M., et al. (1994). Receptor for advanced glycation endproducts (AGEs) has a central role in vessel wall interactions and gene activation in response to circulating AGE proteins. Proc. Nat'l Acad. Sci. USA 91: 8807-8811;
	Schmidt, A. M., et al. (1992). Isolation and characterization of two binding proteins for advanced glycosylation end products from bovine lung which are present on the endothelial cell surface. J. Biol. Chem. 267: 14987-14997;
	Schmidt, A. M., et al. (1994). Cellular receptors for advanced glycation end products. Arterioscler. Thromb. 14:1521-1528;
	Schmidt, A. M., et al. (1995). The dark side of glucose. (News and Views). Nature Medicine 1: 1002-1004;

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Form PTO-1449

Department of Commerce  
Patent and Trademark OfficeAtty. Docket No.  
575-55873-BA-PCT-  
US/JPW/AJM/AABSerial No.  
10/665,867**INFORMATION DISCLOSURE CITATION**  
(Use several sheets if necessary)Applicant(s)  
Ann Marie Schmidt, et al.Filing Date  
September 19, 2003

Group Art Unit

**U.S. PATENT DOCUMENTS**

Examiner Initials	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate

**FOREIGN PATENT DOCUMENTS**

Examiner Initials	Document Number	Date	Name	Class	Subclass	Translation	
						Yes	No

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

AK	Schmidt, A. M., et al. (1993). Regulation of human mononuclear phagocyte migration by cell surface-binding proteins for advanced glycation end products. J. Clin. Invest. 92: 2155-2168;
	Schmidt, A. M., et al. (1997). The V-domain of receptor for advanced glycation endproducts (RAGE) mediates binding of AGEs: a novel target for therapy of diabetic complications. Circulation Supplement 96:#194, p. I-37;
	Schmidt, A. M., et al. (1994). The endothelial cell binding site for advanced glycation end products consists of a complex: an integral membrane protein and a lactoferrin-like polypeptide. J. Biol. Chem. 269: 9882-9888;
	Schmidt, A.M., et al. (1998). RAGE: a receptor with a taste for multiple ligands and varied pathophysiologic states. Hormones and Signaling 1:41-63;
✓	Sell, D., et al. (1989). Structure elucidation of a senescence cross-link from human extracellular matrix; implication of pentoses in the aging process. J. Biol. Chem. 264:21597-21602;


EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.







Form PTO-1449

U.S. Department of Commerce  
Patent and Trademark OfficeAtty. Docket No.  
575-55873-BA-PCT-  
US/JPW/AJM/AABSerial No.  
10/665,867Applicant(s)  
Ann Marie Schmidt, et al.Filing Date  
September 19, 2003

Group Art Unit

**INFORMATION DISCLOSURE CITATION**  
(Use several sheets if necessary)**U.S. PATENT DOCUMENTS**

Examiner Initials	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate

**FOREIGN PATENT DOCUMENTS**

Examiner Initials	Document Number	Date	Name	Class	Subclass	Translation	
						Yes	No

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

AGE	Vlassara, H., et al. (1995). Identification of Galectin-3 as a high affinity binding protein for advanced glycation end products. Arterioscler. Thromb. 14:1521-1528;
	Wautier, J.-L., et al. (1996). Receptor-mediated endothelial cell dysfunction in diabetic vasculopathy: soluble receptor for advanced glycation end products blocks hyperpermeability in diabetic rats. J. Clin. Invest. 97: 238-243;
	Wautier, J.-L., et al. (1996). Interaction of diabetic erythrocytes bearing advanced glycation endproducts with the endothelial receptor AGE induces generation of reactive oxygen intermediates and cellular dysfunction. Circulation Supplement 94(8): #4139;
✓	Wu J., et al. (1997). The soluble receptor for advanced glycation endproducts (sRAGE) ameliorates impaired wound healing in diabetic mice. Plastic Surg. Res. Council Abstract #77, p. 43;

EXAMINER

DATE CONSIDERED

10/11/05

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



<b>Form PTO-1449</b>  <b>U.S. Department of Commerce Patent and Trademark Office</b>  <b>INFORMATION DISCLOSURE CITATION</b> (Use several sheets if necessary)	<b>Atty. Docket No.</b> 575-55873-BA-PCT- US/JPW/AJM/AAB	<b>Serial No.</b> 10/665,867
	<b>Applicant(s)</b> Ann Marie Schmidt, et al.	
	<b>Filing Date</b> September 19, 2003	<b>Group Art Unit</b>

**U.S. PATENT DOCUMENTS**

Examiner Initials	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate

**FOREIGN PATENT DOCUMENTS**

Examiner Initials	Document Number	Date	Name	Class	Subclass	Translation	
						Yes	No

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

	Yan, S. D., et al. (1994). Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J. Biol. Chem. 269: 9889-9897;
	Yan, S. D., et al. (1996). RAGE and amyloid- $\beta$ peptide neurotoxicity in Alzheimer's disease. Nature 382: 685-691;
	Yan, S. D., et al. (1997). Amyloid- $\beta$ peptide-receptor for advanced glycation endproduct interaction elicits neuronal expression of macrophage-colony stimulating factor: a proinflammatory pathway in Alzheimer disease. Proc. Nat'l Acad. Sci. 94: 5296-5301;



**EXAMINER****DATE CONSIDERED**

10/11/05

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



[illegible]

<b>Form PTO-1449</b>		<b>U.S. Department of Commerce</b>		<b>Application Number</b>	<b>10/665,867</b>
		<b>Patent and Trademark Office</b>		<b>Filing Date</b>	<b>September 19, 2003</b>
<b>INFORMATION DISCLOSURE CITATION</b>				<b>First Named Inventor</b>	<b>Ann Marie Schmidt</b>
(Use several sheets if necessary)				<b>Art Unit</b>	
				<b>Examiner Name</b>	
				<b>Attorney Docket No.</b>	<b>55873-BA-PCT-US/JPW/AJM/JCS</b>
<b>NON PATENT LITERATURE DOCUMENTS</b>					
<b>Examiner Initials<sup>1</sup></b>	<b>Cite No.<sup>1</sup></b>	<b>Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.</b>	<b>T<sup>2</sup></b>		
		March 24, 2005 Communication from the European Patent Office transmitting a Supplementary Partial European Search Report Under Rule 45 EPC in connection with European Patent Application No. 99953081.9, filed October 6, 1999			
		Miyata, T., et al., "The receptor for advanced glycation end products (RAGE) is a central mediator of the interaction of AGE- $\beta_2$ microglobulin with human mononuclear phagocytes via an oxidant-sensitive pathway: Implications for the pathogenesis of dialysis-related amyloidosis," Journal of Clinical Investigation 98: 1088-1094 (1996)			
		Hori, O., et al., "The receptor for advanced glycation end-products has a central role in mediating the effects of advanced glycation end-products of the development of vascular disease in diabetes mellitus," Nephrology Dialysis Transplantation 11: 13-16 (1996)			
		Li, J., et al., "Characterization and functional analysis of the promoter of RAGE, the receptor for advanced glycation end products," Journal of Biological Chemistry 272: 16498-16506 (1997)			
		Hofmann, M., et al., "EN-RAGE (extracellular novel-RAGE binding protein) activates endothelial cells and macrophages to mediate inflammatory responses," Circulation 98: 1316 (1998)			
<b>EXAMINER SIGNATURE</b>		<b>DATE CONSIDERED</b> 10/11/2005			
<p><small>* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a checkmark here if English language Translation is attached.</small></p>					